CA2098029A1 - Retrovirus-Like Particles Containing Modified Envelope Glycoproteins - Google Patents

Retrovirus-Like Particles Containing Modified Envelope Glycoproteins

Info

Publication number
CA2098029A1
CA2098029A1 CA 2098029 CA2098029A CA2098029A1 CA 2098029 A1 CA2098029 A1 CA 2098029A1 CA 2098029 CA2098029 CA 2098029 CA 2098029 A CA2098029 A CA 2098029A CA 2098029 A1 CA2098029 A1 CA 2098029A1
Authority
CA
Canada
Prior art keywords
amino acid
acid sequence
retrovirus
retroviral
particles containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2098029
Other languages
French (fr)
Other versions
CA2098029C (en
Inventor
Benjamin Rovinski
Joel Haynes
Shi Xian Cao
Michel Henri Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Connaught Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Laboratories Ltd filed Critical Connaught Laboratories Ltd
Priority to CA 2098029 priority Critical patent/CA2098029C/en
Publication of CA2098029A1 publication Critical patent/CA2098029A1/en
Application granted granted Critical
Publication of CA2098029C publication Critical patent/CA2098029C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Self-assembled, non-replicating, non-infectious retrovirus-like particles contain a chimeric envelope glycoprotein. The envelope glycoprotein comprises a first retroviral amino acid sequence which is substantially homologous with the native retrovirus amino acid sequence and a second retroviral amino acid sequence which is a heterologous amino acid sequence inserted into the first amino acid sequence. Such particles, which may comprise a retroviral surface glycoprotein sequence of HIV-1 or HTLV-1 inserted into the C2 conserved region of an HIV-1 isolate, generally elicit an immune response to at least the heterologous amino acid sequence, preferably both the first and second amino acid sequences.
CA 2098029 1993-06-09 1993-06-09 Retrovirus-like particles containing modified envelope glycoproteins Expired - Lifetime CA2098029C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2098029 CA2098029C (en) 1993-06-09 1993-06-09 Retrovirus-like particles containing modified envelope glycoproteins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2098029 CA2098029C (en) 1993-06-09 1993-06-09 Retrovirus-like particles containing modified envelope glycoproteins

Publications (2)

Publication Number Publication Date
CA2098029A1 true CA2098029A1 (en) 1994-12-10
CA2098029C CA2098029C (en) 2000-10-03

Family

ID=4151769

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2098029 Expired - Lifetime CA2098029C (en) 1993-06-09 1993-06-09 Retrovirus-like particles containing modified envelope glycoproteins

Country Status (1)

Country Link
CA (1) CA2098029C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030523A2 (en) * 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030523A2 (en) * 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
WO1996030523A3 (en) * 1995-03-31 1997-04-17 Hans Wolf Antigen presentation system based on retrovirus-like particles

Also Published As

Publication number Publication date
CA2098029C (en) 2000-10-03

Similar Documents

Publication Publication Date Title
CA2116764A1 (en) Immunoreactive Hepatitis C Virus Polypeptide Compositions
AU1353295A (en) Peptides derived from a retrovirus of the HIV group, and their use
IE850983L (en) Polypeptides with an anticoagulant action
EP0336760A3 (en) Bone-inducing protein
EP0370458A3 (en) Synthetic DNA derived recombinant HIV-1 antigens
AU604033B2 (en) Concentrated aqueous microemulsions
CA2164818A1 (en) Tandem synthetic hiv-1 peptides
EP0339504A3 (en) Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
CA2005502A1 (en) Somatotropin analogs
IL70776A (en) Recombinant dna molecule encoding at least one polypeptide displaying the immunogenicity of at least one merozoite antigen or asexual blood stage antigen of p.falciparum,vectors comprising the dna molecule,host cells transformed thereby,immunogenic polypeptides produced by host cells and compositions containing the polypeptides
EP0307592A3 (en) Analogues of the pancreatic bovine trypsin inhibitor, their production and use
CA2189882A1 (en) Papillomavirus vaccines
AU1179795A (en) Improved immunogenic compositions against human gastrin 17
CA2193210A1 (en) Method of inducing an immune response with a live venezuelan equine encephalitis virus expressing a heterologous immunogen
EP1369427A3 (en) HIV-3 retrovirus strains and their use
EP0140731A3 (en) Natriuretic factors
AU6806187A (en) Pseudorabies virus mutants minus g92 polypeptide
CA2042016A1 (en) Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis
CA2033175A1 (en) Self-assembled, defective, non-self-propagating viral particles
CA2053921A1 (en) Synthetic peptides for an hiv-1 vaccine
CA2098029A1 (en) Retrovirus-Like Particles Containing Modified Envelope Glycoproteins
AU4569293A (en) Anti-feline immunodeficiency virus (fiv) vaccines
IE883545L (en) Peptide structures, immunogens containing them and their uses in the control of fertility
EP0340170A3 (en) Process for the production of polypeptides
WO1997039029A3 (en) An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof

Legal Events

Date Code Title Description
EEER Examination request